Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings
15 April 2005 - 1:30PM
PR Newswire (US)
Abgenix Announces Data Presentations for Panitumumab at AACR and
ASCO Annual Meetings FREMONT, Calif., April 15
/PRNewswire-FirstCall/ -- Abgenix, Inc. (NASDAQ:ABGX) today
announced upcoming presentations of clinical and preclinical data
from studies of panitumumab, a fully human monoclonal antibody
currently in pivotal clinical trials as a third line monotherapy in
colorectal cancer, will be presented at the American Association
for Cancer Research (AACR) annual meeting April 16-20 in Anaheim,
California and the 41st American Society of Clinical Oncology
(ASCO) annual meeting May 13-17 in Orlando, Florida. AACR The
following abstracts are being presented at the AACR meeting: --
"Gene Expression Profiles Can Predict Panitumumab Monotherapy
Responsiveness in Xenograft Models -- A 'Balanced' Approach" will
be presented in the Cellular and Molecular Biology 1, Expression
Profiling and Analysis of Cancer Biology session on Sunday, April
17 from 8:00 a.m. to 12:00 p.m. (Abstract #1); -- "Activity of
Panitumumab Against Mutant and Wild Type EGFr NSCLC Cell Lines and
Xenografts" will be presented in the Molecular Biology 56 session
on Tuesday, April 19 from 1:00 PM to 5:00 PM (Abstract #4494); and
-- "Identification and Preclinical Characterization of EGFr Somatic
Gene Mutations from a Panitumumab Phase 2 NSCLC Clinical Trial:
Discovery of a Novel Mutation with Panitumumab Sensitivity and
Gefitinib Resistance" will be presented in the Late-Breaking Poster
session Tuesday, April 19 from 1:00 p.m. to 5:00 p.m. (Abstract
#LB205). ASCO The following abstracts will be presented at ASCO in
May: -- "Updated Results from a Dose and Schedule Study of
Panitumumab (ABX-EGF) Monotherapy, in Patients with Advanced Solid
Malignancies" will be presented on Sunday, May 15 from 8:00 a.m. to
12:00 p.m. during the General Poster Session; and -- "Safety and
Efficacy of Panitumumab Monotherapy in Patients with Metastatic
Colorectal Cancer (mCRC)" will be presented during a Poster
Discussion on Tuesday May 17 from 8:00 a.m. to 12:00 p.m. About
Panitumumab Co-developed by Amgen and Abgenix, panitumumab is an
investigational product in a novel class of targeted cancer
treatments called epidermal growth factor receptor (EGFr)
inhibitors. Panitumumab (formerly ABX-EGF) is the first fully human
monoclonal antibody directed against EGFr and is being evaluated as
both a monotherapy and in combination with other agents for the
treatment of various types of cancer, including colorectal, lung
and kidney. Panitumumab is generated with Abgenix's XenoMouse(R)
technology, which creates a fully human monoclonal antibody that
contains no murine (mouse) protein. The fully human nature of
panitumumab may result in a favorable safety profile with a low
incidence of infusion reactions, antigenicity and allergic
response. These are attributes currently being investigated in
clinical trials. Pivotal clinical studies evaluating panitumumab as
a third-line monotherapy in colorectal cancer patients are ongoing
with a convenient every-other-week dosing regimen. About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The
company's antibody development platform includes a leading
technology and state-of-the- art manufacturing capabilities that
enable the rapid generation, selection and production of high
affinity, fully human antibody product candidates to a variety of
disease targets. Abgenix leverages its leadership position in human
antibody technology to build a diversified product portfolio
through its own development efforts and the establishment of
collaborations with multiple pharmaceutical and biotechnology
companies. For more information on Abgenix, visit the company's
website at http://www.abgenix.com/. Certain statements in these
materials, including information presented in the letter to
stockholders, are forward-looking statements with the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These include forward-looking
statements about Abgenix's technologies, product development
activities, clinical trials and clinical trial results, the
potential submission of a biologic license application for
panitumumab, collaborative arrangements, process sciences and
manufacturing activities, projected financial and operating
results, and achievement of milestone or similar payments or other
revenues. All such statements are subject to a number of
uncertainties that could cause actual results to differ materially
from the statements made, including risks associated with
conducting clinical trials, regulatory approval processes and
meeting requirements for regulatory approval, the progress of
research and product development programs, product manufacturing,
competitive products and services, capital requirements, the extent
and breadth of Abgenix's patent portfolio, and other factors set
forth in Abgenix's public filings with the Securities and Exchange
Commission. The forward-looking statements included in these
materials are made only as of the date of publication and Abgenix
does not undertake any obligation to update any forward-looking
statements. DATASOURCE: Abgenix, Inc. CONTACT: Ami Knoefler, Senior
Director, Corporate Communications and Investor Relations, of
Abgenix, Inc., +1-510-284-6350, or +1-510-284-6605 Web site:
http://www.abgenix.com/
Copyright
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Abgenix (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Abgenix, (MM) News-Artikel